Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2003;2003(1):CD004023.
doi: 10.1002/14651858.CD004023.

Early versus deferred treatment for early stage multiple myeloma

Y He, K Wheatley, O Clark, A Glasmacher, H Ross, B Djulbegovic
Meta-Analysis

Early versus deferred treatment for early stage multiple myeloma

Y He et al. Cochrane Database Syst Rev. 2003.

Abstract

Background: Early stage multiple myeloma (MM) represents about 20% of MM. Most of the patients are asymptomatic. Thus, it is far less dramatic than advanced disease and may require different treatment strategies. For these patients, it is not clear whether it is better to start chemotherapy right after the diagnosis or to delay the treatment until symptoms become obvious as the disease progresses.

Objectives: To identify and synthesize all available research evidence on whether early treatment intervention results in improved clinical outcomes when compared with observation alone. The main outcomes of interest that were examined included mortality, disease progression, response rate, and toxicity of early treatment.

Search strategy: Searches of the following electronic databases were undertaken: MEDLINE, EMBASE, CANCERLIT, LILLIACS and Cochrane Database of RCTs. We have recently compiled a comprehensive database of RCTs in myeloma. This search was updated and supplemented by hand-search of abstracts from main society meetings such as the ASH (American Society of Hematology), ASCO (American Society of Clinical Oncology), and EHA (European Haematology Association). In addition, we compared our list with a list of RCTs maintained by the Oxford Clinical Trial Service Unit.

Selection criteria: Randomized controlled trials (RCT) with a parallel design that compared early versus deferred treatment of patients with early stage multiple myeloma based on Durie-Salmon (D-S) staging system. We also considered those trials that did not define early stage myeloma according to D-S staging system, but enrolled patients according to clinical uncertainty about the benefits of immediate intervention.

Data collection and analysis: Data synthesis was performed for all studies and according to the defined quality criteria. The first reviewer and the contact reviewer of this proposal independently extracted data. Disagreement was resolved by consensus. Revman software (ver 4.1) was used to combine results from all studies and expressed as an overall odds ratio or Peto's Odds Ratio, with 95% confidence interval.

Main results: Three trials were included with a total of 131 patients in each of the early treatment and deferred treatment groups. Early MM is asymptomatic stage I in these trials. All trials used standard Melphalan treatment but not stem cell transplantation. No statistically significant heterogeneity among the studies was detected. Beneficial effects of early treatment were seen in delay of myeloma progression (Peto's OR = 0.16, 95% CI: 0.09-0.29), and reduced vertebral compression (OR = 0.18, 95%CI: 0.02-1.59, NNT = 23, 95% CI: an NNT of 11, via infinity, to an NNH of 50). No significant effects on mortality and response rate were seen (Peto's OR = 1.11, 95% CI: 0.67-1.84, and OR = 0.63, 95% CI: 0.33-1.23, respectively). Early treatment may increase the risk of acute leukemia (Peto's OR = 3.20, 95% CI: 0.55-18.73, NNH = 44, 95% CI: an NNT of 63, via infinity, to an NNH of 15).

Reviewer's conclusions: Early treatment of early stage multiple myeloma inhibits disease progression, and may reduce vertebral compression. However, early treatment may increase the risk of acute leukemia. However, the data on vertebral compression and leukaemic transformation may not be interpretable due to very small numbers. Based on the current evidence, mortality and response rate are not significantly affected by introducing early treatment in the progression of myeloma. However, it is quite possible that the lack of beneficial effects of early intervention in myeloma is a false negative result due to the paucity of the existing evidence. In addition, data on quality of life and toxicity were sparsely reported adding to additional difficulties about management decisions in early stage myeloma.

PubMed Disclaimer

Conflict of interest statement

Ben Djulbegovic is serves on the editorial board of the Cochrane Haematology Malignancy Group.

Figures

1
1
Forest plot of comparison: 1 Outcome, outcome: 1.1 Mortality.
2
2
Forest plot of comparison: 1 Outcome, outcome: 1.2 Progression.
3
3
Forest plot of comparison: 1 Outcome, outcome: 1.3 Response.
4
4
Forest plot of comparison: 1 Outcome, outcome: 1.4 Vertebral compression.
5
5
Forest plot of comparison: 1 Outcome, outcome: 1.5 Acute leukemia.
1.1
1.1. Analysis
Comparison 1 Outcome, Outcome 1 Mortality.
1.2
1.2. Analysis
Comparison 1 Outcome, Outcome 2 Progression.
1.3
1.3. Analysis
Comparison 1 Outcome, Outcome 3 Response.
1.4
1.4. Analysis
Comparison 1 Outcome, Outcome 4 Vertebral compression.
1.5
1.5. Analysis
Comparison 1 Outcome, Outcome 5 Acute leukemia.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Hjorth 1993 {published data only}
    1. Hjorth M, Hellquist L, Holmberg E, Magnusson B, Rodjer S, Westin J. Initial versus deferred melphalan‐prednisone therapy for asymptomatic multiple myeloma stage I‐‐a randomized study. Myeloma Group of Western Sweden. European Journal of Haematology 1993;50(2):95‐102.. - PubMed
Riccardi 1994 {published data only}
    1. Riccardi A, Ucci G, Luoni R, Brugnatelli S, Mora O, Spanedda R, Paoli A, Barbarano L, Stasi M, Alberio F, et al. Treatment of multiple myeloma according to the extension of the disease: a prospective, randomised study comparing a less with a more aggressive cystostatic policy. Cooperative Group of Study and Treatment of Multiple Myeloma. British Journal of Cancer 1994;70(6):1203‐10.. - PMC - PubMed
Riccardi 2000 {published data only}
    1. Riccardi A, Mora O, Tinelli C, Valentini D, Brugnatelli S, Spanedda R, Paoli A, Barbarano L, Stasi M, Giordano M, Delfini C, Nicoletti G, Bergonzi C, Rinaldi E, Piccinini L, Ascari E. Long‐term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma. British Journal of Cancer 2000;82(7):1254‐60.. - PMC - PubMed

Additional references

Alexanian 1994
    1. Alexanian R, Dimopoulos M. The treatment of multiple myeloma. The New England Journal of Medicine 1994;330(7):484‐9.. - PubMed
Altman 2001
    1. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, Gotzsche PC, Lang T. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Annals of Internal Medicine 2001;134(8):663‐94.. - PubMed
Anderson 1998
    1. Anderson KC, Noga SJ, Bensinger Wea. NCCN practice guidelines for multiple myeloma.. Oncology 1998;12:317‐51. - PubMed
Attal 1996
    1. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. The New England Journal of Medicine 1996;335(2):91‐7.. - PubMed
Castro 1997
    1. Castro AA, Clark AO, Atallah AN. Optimal search strategy for clinical trials in the Latin Anerican and Caribbean Health Science Literature Database (LILIACS).. Revista paulista de medicina 1997;115:1423‐1426. - PubMed
Clarke 1999
    1. Clarke M, Oxman AD. Cochrane Reviewer's Handbook 4.1 [update July 2000]. Oxford: The Cochrane Collaboration; Review Manager (Revman) 4.1. 1999.
Cooper 1986
    1. Cooper MR, McIntyre OR, Propert KJ, Kochwa S, Anderson K, Coleman M, Kyle RA, Prager D, Rafla S, Zimmer B. Single, sequential, and multiple alkylating agent therapy for multiple myeloma: a CALGB Study. Journal of Clinical Oncology 1986;4(9):1331‐9.. - PubMed
Dickersin 1994
    1. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. Bmj 1994;309(6964):1286‐91.. - PMC - PubMed
Djulbegovic 2001
    1. Djulbegovic B, Adams JR, Lyman GH, 23.Djulbegovic B, Adams JR, Lyman GH, et al. Evaluation and appraisal of randomized controlled trials in myeloma.. Ann Oncology 2001;12:1611‐1617. - PubMed
Djulbegovic 2002
    1. Djulbegovic B, Clark O, Hozo I. Database for health outcomes and quality of randomized trials in multiple myeloma. Proceeding of American Society of Clinical Oncology 2002;21:251a.
Durie 1975
    1. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36(3):842‐54.. - PubMed
Egger 2001
    1. Egger M, Smith DS, Altman D. Systematic reviews in health care.. London: BMJ Books 2001;2nd ed.:87‐108.
Harley 1979
    1. Harley JB, Pajak TF, McIntyre OR, Kochwa S, Cooper MR, Coleman M, Cuttner J. Improved survival of increased‐risk myeloma patients on combined triple‐alkylating‐agent therapy: a study of the CALGB. Blood 1979;54(1):13‐22.. - PubMed
Hussein 1994
    1. Hussein M. Multiple myeloma: an overview of diagnosis and management. Cleveland Clinic Journal of Medicine 1994;61(4):285‐98.. - PubMed
Jadad 1996
    1. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1):1‐12.. - PubMed
Jadad 1998
    1. Jadad A. Randomized Controlled Trials.. London: BMJ Books. 1998.
Juni 2001
    1. Juni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. Bmj 2001;323(7303):42‐6.. - PMC - PubMed
Landis 1998
    1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA: a Cancer Journal for Clinicians 1998;48(1):6‐29.. - PubMed
Myeloma 1998
    1. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. Journal of Clinical Oncology 1998;16(12):3832‐42.. - PubMed
Parmar 1998
    1. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815‐34.. - PubMed
Pogue 1997
    1. Pogue JM, Yusuf S. Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta‐analysis. Controlled Clinical Trials 1997;18(6):580‐93; discussion 661‐6.. - PubMed
Robinson 2002
    1. Robinson KA, Dickersin K. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. International Journal of Epidemiology 2002;31(1):150‐3.. - PubMed
Salmon 1983
    1. Salmon SE, Haut A, Bonnet JD, Amare M, Weick JK, Durie BG, Dixon DO. Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group Study. Journal of Clinical Oncology 1983;1(8):453‐61.. - PubMed
Shakespeare 2001
    1. Shakespeare TP, Gebski VJ, Veness MJ, Simes J. Improving interpretation of clinical studies by use of confidence levels, clinical significance curves, and risk‐benefit contours. Lancet 2001;357(9265):1349‐53.. - PubMed
Verhagen 1998
    1. Verhagen AP, Vet HC, Bie RA, Kessels AG, Boers M, Bouter LM, Knipschild PG. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. Journal of Clinical Epidemiology 1998;51(12):1235‐41.. - PubMed